Oppenheimer Sticks to Their Buy Rating for Catabasis Pharmaceuticals (CATB)

By Ryan Adsit

In a report released today, Hartaj Singh from Oppenheimer reiterated a Buy rating on Catabasis Pharmaceuticals (CATBResearch Report), with a price target of $60.00. The company’s shares closed last Monday at $4.66, close to its 52-week low of $4.42.

According to TipRanks.com, Singh is a 4-star analyst with an average return of 2.7% and a 42.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Strongbridge Biopharma.

Catabasis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $18.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.76 and a one-year low of $4.42. Currently, Catabasis Pharmaceuticals has an average volume of 172.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy.